Brief: Perspective Therapeutics Announces First Patient Dosed In Phase 1/2A Dose Escalation Trial For Treatment Of MC1R-Positive Metastatic Melanoma
11/08/2023 13:07
Aug 11 (Reuters) - Perspective Therapeutics Inc
CATX.A :
* PERSPECTIVE THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN
PHASE
1/2A DOSE ESCALATION TRIAL OF VMT01 OF ITS TARGETED
ALPHA-PARTICLE THERAPY (TAT), FOR TREATMENT OF MC1R-POSITIVE
METASTATIC MELANOMA
* PERSPECTIVE THERAPEUTICS INC - PRELIMINARY DATA READOUT
FROM
DOSE ESCALATION STUDY EXPECTED Q4 2023
Source text for Eikon: ID:nGNX93ybhG
Further company coverage: CATX.A
Recent news on Perspective Therapeutics
See all newsPerspective Therapeutics Q2 net loss widens on higher R&D costs
Brief: Perspective Therapeutics Q2 EPS USD -0.22
Brief: Perspective Therapeutics Expands Therapeutic Focus Areas First Patient Dosed With Vmt-Α-Net In The Meningioma Cohort Of A Phase 1/2A Study
Brief: Perspective Therapeutics Q1 EPS USD -0.25
Perspective Therapeutics rises as experimental cancer drug shows promise